Replies to post #417864 on Amarin Corp Plc (AMRN)

[caddiedad]

Absolutely incredible how many times Vascepa is mentioned in this HLS report. Double digits

[Jasbg]

lizzy, Actual rise in revenue for a change 🙂

Q3 & YEAR-TO-DATE ("YTD") 2023 FINANCIAL & OPERATIONAL HIGHLIGHTS

Q3 2023 Vascepa net revenue was C$4.7 million, up 44% compared to C$3.2 million in Q3 2022.
Vascepa total prescriptions in Q3 2023 increased by 89% year-over-year from Q3 2022.
Vascepa prescribers in Q3 2023 increased 86% year-over-year from Q3 2022.
Vascepa consistent prescribers2 in Q3 2023 increased by 97% year-over-year from Q3 2022.

[Nukemtiltheyglow]

Thanks lizzy, seems as though money was well spent as Vascepa revenues increased 3 month (43.7%) and 9 month (45.2%).

Encouraging to see Pfizer is still in the picture with the amended promotional services agreement.
Since Pfizer is staying with Vascepa that is definitely a good sign. It's really only a matter of time and better economic conditions.

Interesting side note: Novartis AG developed Clorazil, it's sales slightly dropped, so the improvement in HLS revenues came from Vascepa sales....very encouraging indeed.